US FDA's Rush Following Novartis' Delay Suggests Strong Displeasure With Handling Of Zolgensma Data Manipulation

Early release of inspection findings is unusual, signaling likelihood that Novartis will face tough scrutiny of its actions, and perhaps stiff fines because of the fraud.